HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

By Shreeya Nanda

The human leucocyte antigen (HLA)-C and killer immunoglobin-like receptor (KIR) genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus (HBV) infection positive for hepatitis B e antigen (HBeAg), say researchers.

Although acknowledging the need for validation in further studies, they believe that "[i]n combination with other known response markers, HLA-C/KIR genotype could enable the selection of patients more likely to respond to interferon-based therapy."

The study included 86 patients treated with combination pegylated interferon alfa-2a and adefovir for 48 weeks and followed up until week 72. At this timepoint, 35% of 41 HBeAg-positive patients and 35% of 45 HBeAg-negative participants demonstrated a combined response, defined as persistently low HBV DNA levels (<2000 IU/mL), normalisation of alanine aminotransferase (ALT) levels and HBeAg loss in those positive for the antigen.

Of 12 single nucleotide polymorphisms (SNPs) located in or near the HLA-C gene, the rs2308557 SNP was the only one significantly associated with response in HBeAg-positive (p=0.003), but not -negative, patients.

This SNP is in almost complete linkage disequilibrium (ie, closely linked to one another) with another that classifies individuals into either the HLA-C1 or HLA-C2 ligand group, whereby each ligand is recognised by a different set of KIRs, explains the team led by Femke Stelma (Academic Medical Center, Amsterdam, the Netherlands).

Among patients positive for HBeAg, the combination of the heterozygous HLA-C2 allele with KIR2DL1, which encodes the KIR receptor that binds to the HLA-C2 ligand, was observed in 13 of 14 responders compared with 11 of 27 nonresponders, a significant difference (p=0.002). By contrast, the homozygous HLA-C2C2 allele together with KIR2DL1 was not associated with response.

Furthermore, multivariable analysis adjusting for HBV genotype and ALT levels showed that the combined KIR2DL1-HLA-C2 genotype was an independent predictor of response in HBeAg-positive individuals.

"HLA-C and KIR genotype is strongly associated with response in HBeAg-positive [chronic HBV] patients treated with interferon-based therapy", the researchers reiterate in the Journal of Viral Hepatitis, adding that the combination could be a "novel marker" in this patient population.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Virus-specific cellular immunity may be essential for long-term protection against SARS-CoV-2